Sonova Holding AG (SONVY)
57.13
+1.09
(+1.94%)
USD |
OTCM |
May 02, 16:00
Sonova Price to Book Value: 7.384 for May 2, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 7.384 |
| May 01, 2024 | 7.243 |
| April 30, 2024 | 7.163 |
| April 29, 2024 | 7.341 |
| April 26, 2024 | 7.283 |
| April 25, 2024 | 7.145 |
| April 24, 2024 | 7.226 |
| April 23, 2024 | 7.219 |
| April 22, 2024 | 7.207 |
| April 19, 2024 | 7.016 |
| April 18, 2024 | 7.009 |
| April 17, 2024 | 7.058 |
| April 16, 2024 | 7.168 |
| April 15, 2024 | 7.217 |
| April 12, 2024 | 7.216 |
| April 11, 2024 | 7.376 |
| April 10, 2024 | 7.232 |
| April 09, 2024 | 7.374 |
| April 08, 2024 | 7.319 |
| April 05, 2024 | 7.230 |
| April 04, 2024 | 7.221 |
| April 03, 2024 | 7.306 |
| April 02, 2024 | 7.230 |
| April 01, 2024 | 7.434 |
| March 28, 2024 | 7.491 |
| Date | Value |
|---|---|
| March 27, 2024 | 7.543 |
| March 26, 2024 | 7.348 |
| March 25, 2024 | 7.361 |
| March 22, 2024 | 7.547 |
| March 21, 2024 | 7.914 |
| March 20, 2024 | 7.865 |
| March 19, 2024 | 7.852 |
| March 18, 2024 | 7.783 |
| March 15, 2024 | 7.930 |
| March 14, 2024 | 8.440 |
| March 13, 2024 | 8.379 |
| March 12, 2024 | 8.356 |
| March 11, 2024 | 8.228 |
| March 08, 2024 | 8.403 |
| March 07, 2024 | 8.284 |
| March 06, 2024 | 8.116 |
| March 05, 2024 | 8.043 |
| March 04, 2024 | 8.082 |
| March 01, 2024 | 8.088 |
| February 29, 2024 | 7.968 |
| February 28, 2024 | 8.003 |
| February 27, 2024 | 8.280 |
| February 26, 2024 | 8.438 |
| February 23, 2024 | 8.515 |
| February 22, 2024 | 8.506 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
4.180
Minimum
Mar 23 2020
10.01
Maximum
Nov 04 2021
7.135
Average
6.880
Median
Sep 04 2020
Price to Book Value Benchmarks
| AC Immune SA | 1.251 |
| CRISPR Therapeutics AG | 2.484 |
| Addex Therapeutics Ltd | 6.936 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.5889 |
Price to Book Value Related Metrics
| PS Ratio | 4.242 |
| Price to Free Cash Flow | 26.17 |
| Price | 57.13 |
| Earnings Yield | 3.87% |
| Market Cap | 17.03B |
| Operating PE Ratio | 22.50 |
| Normalized PE Ratio | 25.86 |